Pharmaceuticals

Therapeutic Nuclear Drug Market Anticipated to Record Steady Gains, Advancing to $4.27 Billion by 2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the therapeutic nuclear drug market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Therapeutic Nuclear Drug Market show for the 2026–2030 period?

The therapeutic nuclear drug market has experienced substantial growth in recent years. It is anticipated to expand from $2.19 billion in 2025 to $2.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.5%. Historically, this market’s expansion has been driven by increasing cancer prevalence, the early adoption of iodine-131 in thyroid disorders, the limited availability of targeted oncology therapies, the expansion of nuclear medicine departments, and the rising clinical acceptance of radiopharmaceuticals.

The therapeutic nuclear drug market is anticipated to experience substantial growth over the next few years, with projections indicating it will reach $4.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.3%. This expansion during the forecast period is primarily driven by the creation of innovative therapeutic isotopes, the broader implementation of precision oncology strategies, increased investment in nuclear medicine infrastructure, a rise in clinical trials for radioligand therapies, and advantageous regulatory approvals for targeted nuclear drugs. Significant trends expected during this time include the increasing adoption of targeted radiopharmaceutical therapies, a growing utilization of lutetium-177 and alpha-emitting isotopes, an expansion in cancer-specific nuclear drug applications, the development of combination therapies incorporating nuclear drugs, and a heightened focus on safety dosimetry and regulatory adherence.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19729&type=smp

What Drivers Are Shaping The Development Of The Therapeutic Nuclear Drug Market?

The rising occurrence of cancer is anticipated to drive expansion in the therapeutic nuclear drug market in the future. Cancer is defined by the uncontrolled multiplication and dispersion of atypical cells. The widespread presence of cancer stems from enhanced detection and diagnosis, lifestyle choices, environmental contact, and genetic predispositions. These therapeutic nuclear drugs serve as an essential tool in the fight against cancer, offering focused and efficient treatment methods for patients by shrinking tumors, easing discomfort, and enhancing overall well-being. For example, in February 2024, the World Health Organization, a Switzerland-based agency of the United Nations, predicted that more than 35 million new cancer cases would emerge by 2050, representing a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the growing incidence of cancer is propelling the development of the therapeutic nuclear drug market.

Which Segments Are Contributing To The Growth Of The Therapeutic Nuclear Drug Market?

The therapeutic nuclear drug market covered in this report is segmented –

1) By Type: Radium-223, Lutetium-177, Iodine-131, Other Types

2) By Distribution Channel: Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Research Institutes

3) By Application: Thyroid, Bone Metastasis, Lymphoma, Other Applications

What Trends Are Projected To Support The Growth Of The Therapeutic Nuclear Drug Market?

Key companies in the therapeutic nuclear drug market are advancing targeted radiotherapies by demonstrating new multi-tumor treatment capabilities through recent clinical data. These endeavors aim to strengthen innovation pipelines, broaden therapeutic uses, and accelerate the adoption of next-generation radiopharmaceuticals. For instance, in 2025, Actinium Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, released new data for ATNM-400, its pioneering Actinium-225 radiotherapy, showcasing its multi-tumor potential, including in non-small cell lung cancer (NSCLC). These findings were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ATNM-400 is engineered to deliver highly potent alpha-particle therapy with precise targeting, supporting its promise as a transformative therapeutic platform across multiple solid tumors. This progression highlights the industry’s dedication to expanding the clinical applications of actinium-based radiotherapies to improve patient outcomes and widen market opportunities.

Who Are The Prominent Global Companies Shaping The Therapeutic Nuclear Drug Market Landscape?

Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/therapeutic-nuclear-drug-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Therapeutic Nuclear Drug Market?

North America was the largest region in the therapeutic nuclear drug market in 2025. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Therapeutic Nuclear Drug Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19729&type=smp

Browse Through More Reports Similar to the Global Therapeutic Nuclear Drug Market 2026, By The Business Research Company

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

Drug Infusion Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-infusion-systems-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795